NAS10030,808+1.00%S&P7,723+0.73%GOLD$4,160−0.06%BTC$85,503+0.87%VIX15.31−6.59%live tape · as of 05:02 UTC
The Screen · Healthcare · Biotechnology
GRI Bio Inc
GRI · NASDAQ · USD · Market cap $3M · 3 employees
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States.
FAIL · Does not pass the screen
1.93 USD
Screen close, 2026-09-18 · not a live quote Last reviewed 17 days ago
Screened 2026-09-18 · the tape above runs as of 05:02 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 1.93 against the desk's fair-value range, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price1.93 USD
Ethical score70.0/100
Our investment reviews on this name
2026-08-31Read Markup1.50+28.7% to today ✓
2026-07-02Read Markdown2.25-14.2% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
GRI Bio Inc holds its Markup at $1.93. The statistical read favours the buyers, held for 67 days.
As held on the ledger · 2026-09-18
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 67 days
Price at the screen
$1.93
Valuation
0.05 trailing · -0.59 forward price to earnings
Values screen
FAIL· score 70.0
Beta
-0.67
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.82%
Below 33%
Interest-bearing debt is just 0.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
94.96%
Below 49%
Money owed to the company is 95.0% of assets, above the 49% limit.
Fail
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
GRI Bio's business is fine, but its receivables are about 95% of its assets, well over the ~49% line, so it does not pass on the financial screens.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
Third-party analyst targets: 2 covering, consensus None. The average target sits +988% from the screen price.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-18 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
GRI trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Markup$1.93+28.7%Entry 6
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 28.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 94%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (2 analysts) rates it none, with a mean price target of $21.
2026-08-31Markup · changed$1.50+0.0%Entry 5
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 94%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (2 analysts) rates it none, with a mean price target of $21.
2026-07-31Markdown$1.50-33.3%Entry 4
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 33.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 94%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (2 analysts) rates it none, with a mean price target of $21.
2026-07-18Markdown$2.25+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 94%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (2 analysts) rates it none, with a mean price target of $21.
2026-07-03Markdown$2.25+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markdown$2.25Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.